The AQUARIUS trial: Aliskiren does not slow progression of atherosclerosis

The renin-angiotensin-aldosterone system (RAAS) appears to have an important role in the development of atherosclerosis.¬† The Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) sought to determine if direct renin inhibition with aliskiren slows atherosclerosis progression in patients with already controlled blood pressure. […]

Read More…